Skip navigation

Bio/Pharmaceutical Legal Congress

Ensure Appropriate Due Diligence to Minimize Corporate Liability in U.S. and Global Operations

June 7-8, 2011
  • Falls Church, Virginia

CBI produces some of the most respected and well attended compliance conferences in the life science industry.  Building off the success within the compliance realm, CBI is offering its Premier Bio/Pharmaceutical Legal Congress. This congress addresses all of the legal challenges that in-house counsel face on a day-to-day basis and provides a forum for benchmarking and networking.    

With increased government focus and negative attention on the pharmaceutical industry, legal departments are faced with assessing and mitigating risk across the company and in the field. Recent Dodd-Frank, Park Doctrine, FCPA and Paragraph IV settlements have legal professionals on high alert. Discuss these cases and discover better ways to perform due diligence to keep your company out of the legal spotlight.

The interactive format allows attendees to choose their own conference agenda and interact directly with their peers in focused settings.

Elite Faculty Includes Perspectives from:

  • FDA Office of the Chief Counsel

  • U.S. Attorney’s Office for the Eastern District of Pennsylvania

  • U.S. Attorney’s Office for the Eastern District of New York

  • U.S. Attorney’s Office for the District of Massachusetts

  • GlaxoSmithKline

  • Pfizer Inc

  • Allergan

  • Lundbeck Inc.

  • Boehringer Ingelheim

  • Mylan Pharmaceuticals

  • Jazz Pharmaceuticals

  • Medicis Pharmaceutical Corporation

  • OSI Pharmaceuticals

  • sanofi-aventis

Also, attendees enjoy shared keynote sessions and networking breaks with attendees from CBI’s 7th Annual Medical Device and Diagnostics Compliance Congress

 

Co-Sponsor and General Counsel Summit Host

 

Fish & Richardson is a leading global law firm with more than 350 attorneys and technology specialists practicing intellectual property strategy and counseling, intellectual property litigation, and business litigation.  Fish does cutting-edge legal work for innovative clients who value their intellectual property. 

For two consecutive years, Fish & Richardson has been named the top U.S. law firm for life sciences and biotechnology work by Managing Intellectual Property magazine. Clients turn to Fish's bio/pharma team to protect their most valuable innovations because of the technical and scientific expertise of our internationally recognized attorneys.  We also have a rapidly expanding practice representing branded pharmaceutical companies in Hatch-Waxman litigation. Biotechnology and pharmaceutical companies trust Fish's litigation team to handle these complicated, high-stakes cases because we are the world's most experienced patent litigators.

Fish’s business litigation group provides expertise in government investigations, compliance issues in regulatory and government enforcement matters, as well as qui tam proceedings under the False Claims Act.  We are well-positioned to service pharmaceutical and medical device companies, as well as any company that works with government contracts, federal grants, military contracts, and the health care industry.

Beyond life sciences, the firm has been ranked the number one patent litigation firm in the country for seven straight years (Corporate Counsel, 2003-2010), a top IP firm for America’s biggest companies (Corporate Counsel, September 2010), and an elite National Tier 1 Intellectual Property Law Firm by U.S. News & World Report (2010).  Fish was honored as an ITC Firm of the Year (Law360, February 2011), an IP Firm of the Year (Law360, January 2010), named a finalist for top IP Litigation Department of the Year (American Lawyer, January 2010), and was named the number one firm in the US for PCT filings (Managing Intellectual Property, October 2010).  For more information, visit http://www.fr.com